




ZIOPHARM Oncology, Inc.
Investor Relations Department
One First Ave., Parris Building, # 34
Navy Yard Plaza
Boston, MA 02199
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ZIOP

Last Trade:	4.27
Trade Time:	12:46 PM ET Jan 16, 2018
Change:	-0.09  (- 2.135%)
Day Range	4.25 - 4.47
52-Week Range	3.77 - 7.88
Volume	837,963


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 9, 2018*
[Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference](#)
- Dec 21, 2017*
[ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)
- Dec 10, 2017*
[ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting](#)
- Nov 20, 2017*
[ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting](#)
- Nov 17, 2017*
[ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)

Financials [\[View all \]](#)

- Feb 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 31, 2017*
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*
[Quarterly Report \(10-Q\)](#)